NATIONAL RESEARCH CORP

NRC Health announced that Shane Harrison, its Chief Financial Officer and principal financial officer, resigned from the company. His resignation is effective August 28, 2026, as he intends to pursue an outside professional opportunity. The company has begun the search for a new Chief Financial Officer.

NRC Health announced its second quarter 2026 financial results, reporting an 11% year-over-year increase in Total Recurring Contract Value (TRCV) to $151.9 million and a 4% rise in total revenue to $35.4 million. The company posted a GAAP net loss of ($3.3) million, or ($0.15) per diluted share, but achieved an Adjusted Net Income of $6.9 million, or $0.31 per diluted share. Additionally, the Board of Directors declared a quarterly cash dividend of $0.16 per share.

National Research Corporation held its 2026 annual meeting on June 23, 2026, where stockholders approved significant amendments to the company's certificate of incorporation. These changes include removing certain supermajority voting requirements, eliminating restrictions on director removal without cause, and modifying the voting requirement for stockholder action by written consent. The Board of Directors also approved conforming amendments to the company's bylaws. Additionally, all seven director nominees were elected, KPMG LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.

NRC Health announced its Annual Meeting of Stockholders to be held virtually on June 23, 2026. The agenda includes the election of seven directors, ratification of KPMG LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Significantly, the company is proposing several amendments to its certificate of incorporation to enhance corporate governance, such as removing supermajority voting requirements, deleting restrictions on director removal without cause, and changing the voting requirement for stockholder action by written consent from unanimous to a simple majority. The Board has also recently declassified itself, with all directors now subject to annual election.

NRC Health reported a significant decrease in net income for Q1 2026, falling 44% to $3.2 million, despite a 3.7% increase in revenue to $34.8 million. Operating income also declined by 35% due to increased operating expenses, including higher stock-based compensation and executive salary expenses. The company also disclosed a subsequent event where amendments to executive equity awards and related bonuses are expected to result in approximately $9.4 million in expenses during Q2 2026.

NATIONAL RESEARCH CORP (NRC) filed an amended 10-K/A for the year ended December 31, 2025, to include previously omitted Part III information covering Directors, Executive Officers, Corporate Governance, and Executive Compensation. The amendment details significant leadership changes in 2025, including the appointment of Trent Green as CEO and Shane Harrison as CFO. Stockholders approved the executive compensation program with approximately 99% of votes cast in favor.

NRC Health filed an Amendment No. 1 to its 2025 Form 10-K to include Part III information, detailing significant leadership changes and corporate governance. Trent Green was appointed CEO, and Shane Harrison became CFO, while founder Michael D. Hays transitioned to Chair. The amendment also outlines executive compensation, board committee structures, and director qualifications.

NRC Health's Compensation Committee amended equity awards for CEO Trent Green, COO Helen Hrdy, and CCO Andrew Monich. The amendments eliminated a repurchase right and included cash bonuses totaling approximately $2.9 million to cover executives' estimated taxes. This action is expected to result in a total expense of approximately $9.4 million in Q2 2026, comprising $6.5 million in non-cash accelerated equity compensation and $2.9 million in cash bonuses.

NRC Health announced strong first quarter 2026 results, with total revenue increasing 4% year-over-year to $34.8 million, marking its first quarter of year-over-year revenue growth since 2023. Total Recurring Contract Value (TRCV) grew 13% to $152.1 million, and net cash flow from operating activities rose 8% to $7.2 million. The company also reported signing the largest deal in its 45-year history and declared a quarterly cash dividend of $0.16 per share.

NRC Health, formerly National Research Corporation, officially changed its corporate name to NRC Health, effective April 15, 2026. This rebranding was enacted via an amendment to its certificate of incorporation, with no change to its 'NRC' NASDAQ ticker symbol. Concurrently, the Board of Directors adopted amended and restated Bylaws, and the Compensation and Talent Committee modified an executive's restricted stock award to permit voting and dividend rights on unvested shares.